InSightec’s ExAblate Neuro System Awarded European CE Mark for Non-invasive Treatment of Neurological Disorders in the Brain
TIRAT CARMEL, Israel, December 4, 2012 /PRNewswire/ –
ExAblate treatment is indicated for use for essential tremor, tremor
dominant Parkinson’s disease and neuropathic pain
InSightec Ltd. announced that its transcranial focused ultrasound system, ExAblate
Neuro, has been awarded the European CE mark for the treatment of neurological disorders
in the brain including essential tremor, Parkinson’s disease and neuropathic pain.
Millions of people suffer from neurological disorders which cause significant
disability and negatively affect their quality of life and that of their caretakers.
Treatment options for patients who do not respond to drug treatments include deep brain
stimulation, radiofrequency ablation and radiosurgery which are invasive or involve
ionizing radiation and are associated with recognized risks: high doses of ionizing
radiation or high risk of complications and side effects including infection, bleeding and
collateral brain tissue damage.
“ExAblate offers great potential for treating brain disorders. Because of its
targeting accuracy, real time treatment monitoring and ability to provide non- invasive
brain treatment, there is hope that many people who suffer from neurological diseases can
benefit from this treatment,” said Dr. Kobi Vortman, President of InSightec. “Results from
the clinical studies showed that patients, many of whom who suffered for years from
neurological disorders, experienced immediate symptom improvement with a high safety
profile. These patients are now better able to conduct activities of daily living and are
also less dependent on external caregiver support.”
“ExAblate(R) Neuro offers a non-invasive treatment with no ionizing radiation, which
treats tissue deep in the brain through an intact skull. MR guided Focused ultrasound
(MRgFUS) combines therapeutic acoustic ultrasound waves with continuous MRI guidance,”
added Eyal Zadicario, Vice President of R&D and Director of InSightec’s Neuro program.
“The MRI enables physicians to visualize, plan, guide, monitor and control the treatment
while the ultrasound acoustic energy destroys the targeted tissue in the brain.”
InSightec recently received its second ExAblate FDA approval for the treatment of
painful bone metastases in patients who are unable or unwilling to undergo radiation. This
is in addition to FDA approval for the treatment of uterine fibroids received in 2004. The
CE marking enables ExAblate Neuro to be sold in Europe.
InSightec [http://www.insightec.com ] Ltd. is privately held by Elbit Imaging, General
Electric, and MediTech Advisors. Founded in 1999 InSightec developed ExAblate to transform
MRI-guided Focused Ultrasound (MRgFUS) into a clinically viable technology. ExAblate has
won several awards for innovation and its potential to help mankind including The Wall
Street Journal Technology Innovation Awards and the European Union’s IST grand prize. TIME
magazine recently named Focused Ultrasound as “one of 50 best inventions”. For more
information about treatment centers and brain disorders please visit:
Media contact: Lynn Golumbic +972-4-813-1380 email@example.com
SOURCE InSightec Ltd